Sandbox:Roukoz: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
Line 41: Line 40:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis
* 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis
Line 59: Line 57:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule
|-
|-
Line 76: Line 73:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth)
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth)
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Two-thirds arise in normal skin, the rest in existing moles
* Two-thirds arise in normal skin, the rest in existing moles
Line 95: Line 91:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Do not make melanin, so lesions are not pigmented
* Do not make melanin, so lesions are not pigmented
Line 114: Line 109:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 133: Line 127:
* large, hyperchromatic, oval nuclei and little cytoplasm
* large, hyperchromatic, oval nuclei and little cytoplasm
* well differentiated and cells appear histologically similar to basal cells of the epidermis
* well differentiated and cells appear histologically similar to basal cells of the epidermis
| style="background: #F5F5F5; padding: 5px;" |skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 150: Line 143:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 158: Line 150:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone.
| style="background: #F5F5F5; padding: 5px;" |Other sites lungs, liver, brain, skin, or bone.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 171: Line 162:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign Skin Lesions'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 192: Line 182:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Yellow-nodule
| style="background: #F5F5F5; padding: 5px;" |Yellow-nodule
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 206: Line 195:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Rhabdomyosarcoma'''
| style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid
| style="background: #F5F5F5; padding: 5px;" |Bulging of the eye or a swollen eyelid
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 235: Line 223:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 241: Line 228:
| style="background: #F5F5F5; padding: 5px;" |Hard lesion
| style="background: #F5F5F5; padding: 5px;" |Hard lesion
| style="background: #F5F5F5; padding: 5px;" |Itchy lumps
| style="background: #F5F5F5; padding: 5px;" |Itchy lumps
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 269: Line 255:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |chronic
| style="background: #F5F5F5; padding: 5px;" |chronic
|-
|-
Line 282: Line 267:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Skin biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 294: Line 278:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Verrucous lesion
| style="background: #F5F5F5; padding: 5px;" |Verrucous lesion
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 313: Line 296:
| style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped
| style="background: #F5F5F5; padding: 5px;" |Red, dome-shaped
| style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale
| style="background: #F5F5F5; padding: 5px;" |Friable papule with a collarette of scale
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 328: Line 310:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that  
| style="background: #F5F5F5; padding: 5px;" |multiple, red- to brown-colored, small papules that  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 348: Line 329:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Coin shaped spots
| style="background: #F5F5F5; padding: 5px;" |Coin shaped spots
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 365: Line 345:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin
| style="background: #F5F5F5; padding: 5px;" |Thick, white, silvery, or red patches of skin
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 383: Line 362:
| style="background: #F5F5F5; padding: 5px;" |Purulent ulcer
| style="background: #F5F5F5; padding: 5px;" |Purulent ulcer
| style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border
| style="background: #F5F5F5; padding: 5px;" |Ragged and violaceous border
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 395: Line 373:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Venous stasis ulcers'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 412: Line 389:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Traumatic ulcers'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 433: Line 409:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red scaly patch
| style="background: #F5F5F5; padding: 5px;" |Red scaly patch
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 454: Line 429:
Yellowish, soft, small papules on the face  
Yellowish, soft, small papules on the face  
| style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead
| style="background: #F5F5F5; padding: 5px;" |Usually on the nose, cheeks, and forehead
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 469: Line 443:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 486: Line 459:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |Red rash
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 503: Line 475:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule  
| style="background: #F5F5F5; padding: 5px;" |Erythematous, dome-shaped papule  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 516: Line 487:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Nevus'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 533: Line 503:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Chemical Burns'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 563: Line 532:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue  
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Benign hereditary intraepithelial dyskeratosis'''


| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 585: Line 552:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''primary acquired melanosis'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 615: Line 581:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism


Line 624: Line 589:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented
| style="background: #F5F5F5; padding: 5px;" |Inflamed and hyperpigmented
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 642: Line 606:
| style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions  
| style="background: #F5F5F5; padding: 5px;" |Reddened, yellowish-tan color of lesions  
| style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps
| style="background: #F5F5F5; padding: 5px;" |Slightly raised bumps
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 654: Line 617:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous fungal infections'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 671: Line 633:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Desmoplastic trichoepithelioma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 688: Line 649:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Adnexal carcinoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 705: Line 665:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 722: Line 681:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Darier disease'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 739: Line 697:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous T-cell lymphoma'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 763: Line 720:
| style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins
| style="background: #F5F5F5; padding: 5px;" |Rolled or everted wound margins
| style="background: #F5F5F5; padding: 5px;" |Bleeding on touch
| style="background: #F5F5F5; padding: 5px;" |Bleeding on touch
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 782: Line 738:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 792: Line 747:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Anogenital'''
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 816: Line 770:
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |Dome-shaped or crateriform nodules with a central keratotic core
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |Increased size
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 17:31, 14 February 2019

Diseases Clinical manifestations Para-clinical findings Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3 Imaging 1 Imaging 2 Imaging 3
Cutaneous squamous cell carcinoma Pain Erythema Indurated Hyperkeratotic Increased size
  • 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis
Merkel cell carcinoma Starts on areas of skin exposed to the sun Single pink, red, or purple shiny bump Painless Blue-red, dome-shaped nodule
Nodular malignant melanoma Lump that has been rapidly growing over the past weeks Cells proliferate downwards through the skin (vertical growth)
  • Two-thirds arise in normal skin, the rest in existing moles
  • Genetic component in some cases with a positive family history
Amelanotic melanoma Color usually pink, purple or normal skin color Usually have an asymmetrical shape with an irregular border Red, nonspecific lesion with slightly elevated borders
  • Do not make melanin, so lesions are not pigmented
Basal cell carcinoma Coarse scale lesion
Superficial basal cell carcinoma Scaly patch Erythematous lesion
  • large, hyperchromatic, oval nuclei and little cytoplasm
  • well differentiated and cells appear histologically similar to basal cells of the epidermis
Nodular basal cell carcinoma Pearly papule with telangiectasias
Cutaneous metastases of internal malignancy Other sites lungs, liver, brain, skin, or bone. The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes;
Benign Skin Lesions
Sebaceous cell carcinoma Yellow-nodule Suspected due to evidence of eyelash loss
Rhabdomyosarcoma Bulging of the eye or a swollen eyelid Develops in skeletal muscles usually
Actinic keratoses Pain Hyperkeratosis Erythema less pigmentation, and tend to be somewhat smaller in size.
Prurigo nodules Hard lesion Itchy lumps
Paget disease Eczema-like rash of the skin Around the genital regions of males and females. Similar to mammary paget disease chronic
Inflamed seborrheic keratosis Waxy, "stuck on," often hyperkeratotic appearance
Viral warts Verrucous lesion Caused by HPV
Pyogenic granuloma Rapidly growing Red, dome-shaped Friable papule with a collarette of scale
Bowenoid papulosis multiple, red- to brown-colored, small papules that
  • primarily arise on genitals
  • induced by human papillomavirus (HPV) infection
Nummular eczema Itchy lesions Coin shaped spots Chronic condition
Psoriasis Flaking, inflammation Thick, white, silvery, or red patches of skin Chronic condition
Pyoderma gangrenosum Purulent ulcer Ragged and violaceous border
Venous stasis ulcers
Traumatic ulcers
Bowen Disease Red scaly patch Very early form of skin cancer that is very treatable

referred to as squamous cell carcinoma insitu

Sebaceous Hyperplasia Lesions can be single or multiple lesions

Yellowish, soft, small papules on the face

Usually on the nose, cheeks, and forehead
Allergic Contact Dermatitis Itchy rash Red rash Not contagious
Atopic Dermatitis Itchy rash Fever Red rash Chronic and sometimes accompanied by asthma
Atypical Fibroxanthoma Erythematous, dome-shaped papule
Nevus
Chemical Burns
Limbal Dermoid Contains choristomatous tissue Benign congenital tumor
Benign hereditary intraepithelial dyskeratosis Rare autosomal-dominant disorder of the conjunctiva and oral mucosa
primary acquired melanosis
Fibrous xanthoma Containing fibromatous elements Arises due to disturbed systemic lipid metabolism
Inflamed seborrheic keratosis Inflamed and hyperpigmented
Juvenile xanthogranuloma Reddened, yellowish-tan color of lesions Slightly raised bumps Typically
Cutaneous fungal infections
Desmoplastic trichoepithelioma
Adnexal carcinoma Very rare
Keratoacanthoma
Darier disease Keratosis follicularis
Cutaneous T-cell lymphoma Mycosis fungoides
Marjolin's ulcer Lesions in sites of chronic wounds and scars Excessive granulation tissue, Rolled or everted wound margins Bleeding on touch
  • rare type of SCC
  • Very slow malignant transformation
Epithelioma cuniculatum Increased size Verrucous carcinoma on the plantar foot
Anogenital also known as giant condyloma acuminatum of Buschke-Loewenstein
Keratoacanthoma Found on actinically damaged skin Rapid initial growth Dome-shaped or crateriform nodules with a central keratotic core Increased size keratocytic epithelial tumors